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We next exposed infected host cells 
to lysosomotropic alkalinizing agents to 
examine whether neutralizing lysosomal 
pH would reduce the formation of SCVs. 
Analysis of an average percentage of SCVs 
from 3 independent experiments revealed 
that host cells treated with alkalinizing 
agents exhibited lower percentages of SCVs 
7 days after infection (Figure 1E and F). In 
1 of 3 events, however, there was a peak in 
SCV percentage at day 5 for ammonium 
chloride–treated host cells infected with 
S.  aureus 6850 and S.  epidermidis IDRL-
8933, resulting in a large mean standard 
deviation at that time point (Figure 1F). No 
differences were observed in total colony 
counts between cells that were and those 
that were not treated (Figure 1D).
In conclusion, low pH and the intracel-
lular environment promote the formation 
of S.  epidermidis SCVs. Acidic environ-
ments, such as within lysosomes or pha-
gosomes, may induce SCV formation for 
S. aureus and S. epidermidis.
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Reply to Perez and Patel 
To the Editor—We thank Perez and 
Patel for taking our recent observation 
on Staphylococcus aureus small-colony 
variants (SCVs) a step further [1]. We 
reported that low pH and intracellular 
localization promotes S. aureus SCV for-
mation and that the frequency of SCVs is 
reducible by phagolysosomal alkaliniza-
tion. Now Perez and Patel show that the 
same is true for select Staphylococcus epi-
dermidis strains, including those derived 
from prosthetic joint infections [2].
The capability of S. aureus to reside and 
persist intracellularly is strain dependent, 
owing to differences in the presence and 
expression of virulence factors, and is also 
host-cell dependent [3]. This is most likely 
also true for S. epidermidis. The long-term 
S.  aureus intracellular persistence model 
that we used in our study consisted of 
the human lung carcinoma cell line A549 
and S.  aureus strain Cowan. A549 cells 
are very robust and only exhibit limited 
sensitivity to S. aureus–induced cell dam-
age [4]. S. aureus strain Cowan is highly 
invasive and does not express certain vir-
ulence factors, resulting in reduced host 
cell damage [5]. By exchanging the tissue 
culture medium daily, we maintained 
the antibiotic pressure constant over the 
course of infection. Discrepancy between 
the numbers of viable intracellularly per-
sisting bacteria in the study by Perez and 
Patel and ours, thus, is most probably due 
to the use of another host cell line and 
another S.  aureus strain. The S.  aureus 
strain 6850 used as a control by Perez and 
Patel has been shown to modulate phago-
lysosomal pH, escapes phagolysosomes, 
and is cytotoxic [6].
In conclusion, low pH and intracel-
lular localization promote formation of 
S.  aureus and S.  epidermidis SCVs. The 
frequency of these SCVs is reducible by 
chloroquine. These observations are most 
likely also applicable to other intracellu-
lar persisting bacterial infections.
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Codon 91 Gyrase A Testing 
Is Necessary and Sufficient 
to Predict Ciprofloxacin 
Susceptibility in Neisseria 
gonorrhoeae
To the Editor—We read with great 
interest the article by Grad et al [1]. We 
agree with their conclusion that gyrase 
A  (gyrA) genotype testing of Neisseria 
gonorrhoeae is a valuable means of re-
sistance testing; however, we believe that 
gyrA testing, specifically of codon 91, is 
both necessary and sufficient for predict-
ing susceptibility to ciprofloxacin. There 
have been 11 studies (N=4777 specimens) 
comparing real-time polymerase chain 
reaction (RT-PCR) genotype results with 
conventional antimicrobial susceptibil-
ity testing methods, all of which have 
demonstrated high sensitivity and spec-
ificity (93.8%–100% and 93.2%–100%, 
respectively). Positive and negative pre-
dictive values were similarly impressive 
(94.4%–100% and 87.5%–100%, respec-
tively). Furthermore, 4 studies found that 
mutation at codon 91 of the gyrA gene as 
determined by RT-PCR was 100% specif-
ic for N. gonorrhoeae compared with oth-
er Neisseria species [2–5].
Other mutations have been shown to 
contribute to ciprofloxacin resistance, but 
previous studies have shown that other 
mutations in general occur in conjunction 
with a mutation in the gyrA gene [6, 7]. 
In addition, it is estimated that approxi-
mately 80% of N. gonorrhoeae infections 
in the United States are susceptible to cip-
rofloxacin [8]. Those 2 facts support the 
implementation of gyrA genotype testing 
to promote the use of targeted ciprofloxa-
cin therapy. That may in turn reduce over-
use of ceftriaxone. A recent article showed 
that treatment may be a major driver of 
ceftriaxone resistance in Neisseria gonor-
rhoeae [9], which has been called one of 
the top 3 urgent threats to public health 
by the Centers for Disease Control and 
Prevention [10].
We developed a rapid codon 91 gyrA 
genotypic assay using RT-PCR tech-
niques [6], and we verified the assay in 
accordance with Clinical Laboratory 
Improvement Amendments [2]. UCLA 
Health introduced that assay into rou-
tine clinical practice for all N. gonorrhoe-
ae–positive specimens in November 2015. 
Further studies are underway to charac-
terize the impact of that implementation.
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Reply to Allan-Blitz and 
Klausner
To the Editor—We thank Allan-Blitz 
and Klausner [1] for the citations to their 
group’s work in this area and to the ef-
forts underway to test diagnostics for 
quinolone resistance in Neisseria gon-
orrhoeae. Although our study investi-
gated the genetic basis of resistance and 
assessed the positive and negative pre-
dictive values of specific mutations for 
resistance in the set of samples we ana-
lyzed [2], we take no position on the suit-
ability of particular diagnostics. We note, 
however, that the US Food and Drug 
Administration has published guidance 
for antimicrobial susceptibility test sys-
tems [3]. The lower end of the range in 
negative predictive value cited by Allan-
Blitz and Klausner (87.5%) is consider-
ably lower than the 99% we observed, 
